|Bid||23.97 x 900|
|Ask||25.12 x 900|
|Day's Range||23.75 - 24.70|
|52 Week Range||14.21 - 37.75|
|Beta (5Y Monthly)||2.58|
|PE Ratio (TTM)||6.33|
|Earnings Date||Nov 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.31|
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […]
SAN DIEGO, December 04, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m.
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.